Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Browse By Topic
Personalized Medicine
Personalized Medicine
Articles about personalized medicine on Value-Based Cancer Care. Learn how to utilize a patient's unique genetic makeup and environment to customize the patient's medical care and treatment.
Filter by Topic
Cancer Care
Cancer Drugs
Cancer Prevention
Cancer Quick Takes
Cancer Rehabilitation
Cancer Screening
Cervical Cancer
Chemotherapy
Clinical Research
Clinical Trials
Emerging Therapies
Genetic Testing
Hematologic Malignancies
Hormone Therapy
Immunotherapy
Multidisciplinary Care
Palliative Care
Pregnancy & Cancer
Prognostic Tests
Radiation Therapy
Radiotherapy in Focus
Sentinel Node Management
Solid Tumors
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
Emerging Therapies
,
Personalized Medicine
August 2015, Vol 6, No 7
A clinical trial has shown that patients with a specific molecular subtype of diffuse large B-cell lymphoma (DLBCL) are more likely to respond to the drug ibrutinib (Imbruvica) than patients with another molecular subtype of the disease. The study appeared online July 20, 2015, in
Nature Medicine
.
Read Article
GADOLIN Trial: Obinutuzumab an Effective Treatment for Indolent Lymphoma
By
Phoebe Starr
Emerging Therapies
,
Personalized Medicine
August 2015, Vol 6, No 7
Chicago, IL—The results of the phase 3 GADOLIN trial provide the first proof of efficacy for obinutuzumab (Gazyva) in patients with indolent non-Hodgkin lymphoma (NHL). Obinutuzumab added to standard bendamustine (Treanda) chemotherapy almost doubled progression-free survival (PFS) in patients with rituximab (Rituximab)-refractory indolent lymphoma—the median PFS was 29.2 months with obinutuzumab plus bendamustine versus 14 months with bendamustine alone.
Read Article
Genomic Sequencing for Pancreatic Cancer Still Facing Hurdles
By
Phoebe Starr
Personalized Medicine
June 2015, Vol 6, No 5
Philadelphia, PA—Although whole genomic sequencing can be done on a patient’s tumor, it does not mean that this will translate to a patient’s getting targeted therapy to identified genetic abnormalities, especially if that patient has pancreatic cancer.
Read Article
Biomarker Testing Trends in Europe Linked to Availability of Specific Targeted Cancer Drugs
By
Laura Morgan
Personalized Medicine
June 2015, Vol 6, No 5
Philadelphia, PA—In an era of personalized care, targeted cancer therapies are on the rise and are expected to reach nearly 60% of the global oncology and hematology drug markets by 2017. By testing for genetic biomarkers, physicians can predict patient response to cancer therapy and identify patients who will benefit most from these treatments, thus serving the 2 purposes of increasing the efficiency of treatment decisions and reducing the use of unnecessary drug prescribing and the associated costs.
Read Article
Adding Ibrutinib to Standard Therapy Reduces Disease Progression by 80% in Previously Treated Patients with CLL
By
Phoebe Starr
Palliative Care
,
Personalized Medicine
June 2015, Vol 6, No 5
Chicago, IL—The combination of ibrutinib (Imbruvica) plus standard therapy with bendamustine (Treanda) and rituximab (Rituxan) significantly reduced the risk for disease progression or death by 80% compared with bendamustine plus rituximab alone in previously treated patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), according to lead investigator Asher A. Chanan-Khan, MD, Chair, Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL.
Read Article
Early Initiation of Palliative Care Improves Survival in Patients with Advanced Cancer
By
Laura Morgan
Palliative Care
,
Personalized Medicine
June 2015, Vol 6, No 5
Palliative care offers symptom relief, comfort, and peaceful death to patients with advanced cancer. Historically, palliative care was provided to patients who were near death. Based on recent research, however, the American Society of Clinical Oncology now recommends combining palliative care with curative treatment early in the disease course. Nevertheless, an important question remains: How early in the disease trajectory should patients with advanced cancer begin receiving palliative care?
Read Article
Clinical Utility of Genomic Biomarker Tests Questioned
By
Alice Goodman
Personalized Medicine
April 2015, Vol 6, No 3
Orlando, FL—An independent review of the literature suggests that 3 biomarker tests developed for prostate cancer have yet to justify their utility in randomized clinical trials. The 3 tests in question—Prolaris, Decipher, and Oncotype DX for prostate cancer—are being used in practices around the country, cost approximately $3500 per test, and are reimbursable by Medicare depending on the state.
Read Article
What Patients Really Want from Their Care Team
By
Linda D. Bosserman, MD, FACP
Personalized Medicine
Videos
Dr. Bosserman explains that in her practice, patients want to be involved in their care. They want the truth about their disease, treatment, outcomes, and cost, and they want to hear it from their doctor.
Read Article
Using Research to Guide Quality and Quantity of Care
By
Andrew Stainthorpe, PhD
Personalized Medicine
Videos
Oncologists should be guided by the research that is being done around outcomes, benefit, and society impact when making value-based care decisions, says Dr. Stainthorpe.
Read Article
Bringing the Patient into the Conversation
By
Andrew Stainthorpe, PhD
Personalized Medicine
Videos
Dr. Stainthorpe shares his belief that when it comes to care decisions, oncology patients should be provided with information about the benefits/outcomes/consequences and cost of their care.
Read Article
Page 19 of 35
16
17
18
19
20
21
22
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma